Protalix Has Booked Most of Its 2026 Revenue Target Before Q4 Begins

Protalix BioTherapeutics has already booked most of its 2026 revenue target. The company reported on 10 November that revenue for the first nine months was $75.6m, with net income of $26.1m. It said it expects full-year revenue to meet or exceed its guidance range of $78m to $83m.

By our arithmetic, not a figure supplied by the company, the nine-month total leaves $2.4m to reach the bottom of that range and $7.4m to reach the top. The material available did not include a quarterly breakdown or a revenue split by product or customer, so the sources of the revenue and the shape of the fourth quarter cannot be assessed here.

Separately, Elfabrio, the Fabry disease treatment Protalix develops with Chiesi, has been cleared for sale in Brazil. The approval covers dosing every two weeks and every four weeks. The approval date was not available. No Brazilian launch timetable, pricing or reimbursement plans were disclosed. The Chiesi partnership is central to Elfabrio's commercial reach, so any rollout there is likely to run through that relationship.

In the pipeline, Protalix is still recruiting patients for RELEASE, a Phase 2 trial of PRX-115 in uncontrolled gout. Top-line results are expected in the second half of 2027, so the programme is unlikely to move the company's numbers in the near term. Study design details were not available.